In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Mizuki YamaneResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan, Correspondence[email protected]

Kosuke KawashimaResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Koji YamaguchiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Shunsuke NagaoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Mika SatoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Masayuki SuzukiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Kiyofumi HondaResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Hitoshi HagitaChugai Research Institute for Medical Science, Inc., Shizuoka, Japan,

Olaf KuhlmannRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, and

Agnes PoirierRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, and

Stephen FowlerRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, and

Christoph FunkRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, and

Sandrine SimonRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, and

Yoshinori AsoResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Sachiya IkedaProject & Lifecycle Management Unit, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

Masaki IshigaiResearch Division, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan,

Your download is now in progress and you may close this window